Plain-English translation of NCT07477600 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called clonal fetal mesenchymal stem cells (cfMSCs) for people with moderate to severe COPD whose regular medications aren't working well enough. These are special healing cells grown in the lab that may be able to repair damaged lung tissue and calm down the excessive inflammation in the lungs. The trial will check whether this treatment is safe and whether it can help people breathe better.
Current COPD medications can help with symptoms and slow disease progression, but they cannot actually repair the damaged lung structures. This medication is being tested because it might be able to regenerate lung tissue and reduce harmful inflammation, offering hope for people whose standard treatments have not been effective.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the stem cell treatment at the study center. The trial will monitor your safety and how well the treatment works by checking your lung function, breathing ability, and inflammation levels over time through visits and tests. The study involves 30 participants total and will help researchers determine the best dose and way to give this treatment, as well as how long the benefits last.
AI-generated summary from trial data · Jun 20, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Shenzhen Geno-Immune Medical Institute
Enrollment target
~30 participants
Started
March 2026
Primary completion
March 2029
Age range
40 Years – 80 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lung-Ji Chang, Ph.D
Shenzhen Geno-Immune Medical Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.